Prospective, randomized, non-blind, comparative with parallel groups, multicenter and multinational phase IH clinical study of the efficacy and safety of moxifloxacin 400 mg od sequential therapy versus amoxicillin/clavulanate 1 g IV tid followed by amoxicillin/clavulanate 625 mg PO tid for the treatment of complicated skin and skin structure infections during a 21-day period (Study 10279)

BAYER S.A.,0 个研究点目标入组 0 人2001年3月30日

概览

阶段: 未知
干预措施: 未指定
疾病 / 适应症: 未指定
发起方: BAYER S.A.,
状态: 已完成
最后更新: 2年前

概览研究者入排标准结局指标相似试验

概览

简要总结

暂无简介。

注册库

who.int

开始日期

2001年3月30日

结束日期

待定

最后更新

2年前

研究类型

Interventional

研究者

发起方

BAYER S.A.,

入排标准

入选标准

•Patients \>\= 18 years of age were eligible for enrolment if they had a cSSSI at one site only, if it was anticipated that they required systemic antimicrobial therapy, and if they had had a sample culture taken within 24 h prior to being included in the study.
•Patients with pathogens showing in vitro resistance to the study drugs could be included based on the judgment of the investigator.
•In this study, the following cSSSI diagnoses were prospectively defined: diabetic foot infection, necrotizing fasciitis, post\-surgical wound infection, complicated cellulitis, complicated erysipelas, major abscess of the skin, infection of traumatic lesion, and infected ischemic ulcer.
•Patients also had to have one of the following signs and symptoms – fever \>0 38\.0 °C axillary or \>\= 38\.5 °C orally; leukocytosis (absolute white blood cell \[WBC] count \> 10,000 cells/ml) with neutrophilia (\> 80% neutrophils), tachycardia (\> 90 beats per minute), increased respiratory rate (\> 20 breaths per minute), or elevated C\-reactive protein (CRP) – plus two or more of the following signs and symptoms within 24 h preceding enrolment: local pain or tenderness, anesthesia or hypoesthesia of the affected area, swelling of the presumed affected area, purulent, serosanguinous, ‘dishwater’ or foul\-smelling discharge, gas formation detected under the skin, and changes in the appearance of the involved area, such as discoloration of skin, presence of black necrotic areas, red\-brown or hemorrhagic bullae, or skin color changes from red\-blue to patches of bluegrey.

排除标准

•Patients with diagnoses of uncomplicated mild\-to\-moderate SSSIs and of secondary infected burns, atopic dermatitis, or eczema were excluded from the study.
•Women who were pregnant or nursing
•Patients with severe life\-threatening diseases with a life expectancy \< 2 months
•End\-stage liver cirrhosis (Child–Pugh C)
•Severe renal impairment requiring dialysis
•Septic shock
•Patients receiving chronic immunosuppressant treatment
•Neutropenia (neutrophils absolute count \<\= 1,000 cells/ml)
•AIDS stage 1 or 2 (CD4\+ absolute count \< 200 cells/ll)
•HIV\-seropositive individuals receiving highly activated antiretroviral treatment.

结局指标

主要结局

未指定

相似试验

进行中（未招募）

2 期

Comparative study between Standard Dressing and Standard Dressing with Plant Extract of Jamelão in the treatment of Wounds on lower limbs

RBR-9tqcr5qGilson Roberto de Araujo

已完成

不适用

Comparative, Double-blind, Randomized, Prospective, Multicenter Study to Evaluate the Local Tolerability of MK-0826 versus Sodium Ceftriaxone Administered by the Intramuscular Route.

PER-027-00MERCK SHARP & DOHME PERU S.R.L.,

招募中

4 期

A comparative clinical study to evaluate the safety and performance of capsular tension ring.Health Condition 1: H259- Unspecified age-related cataract

CTRI/2023/03/050397Grewal Eye Institute

进行中（未招募）

4 期

A comparative study to evaluate the efficacy and safety of Troxipide (100 mg) and Rabeprazole (20 mg) alone and in combination in patients of Acid peptic disorders.Health Condition 1: null- Acid Peptic Disorder

CTRI/2013/09/003944Government Medical College Hospital100

进行中（未招募）

1 期

Efficacy of nebulized 4.2% sodium-bicarbonate in COVID-19 pneumoniasevere COVID-19 pneumonia requires invasive ventillatory supportMedDRA version: 23.1Level: LLTClassification code 10084564Term: SARS-CoV-2 pneumoniaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]

EUCTR2021-001665-20-HUSemmelweis University Department of Oralbiology200